Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD-GA-102 in advanced colorectal cancer
NCT07050394Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD-GA-102 in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Objective Response Rate at 24 months. Started Jun 2025; status: recruiting.
02
Drugs
CD-GA-102
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07050394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07050394.